Otto Kauko

Otto Kauko

Auto-generated profile, based on publicly available information

Otto Kauko

University of Turku

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2021 in Cell
Verified
Journal Article
Closed access
SVStephin J. Vervoort
Stephin J. Vervoort
SWSarah A. Welsh
Sarah A. Welsh
JDJennifer R. Devlin
Jennifer R. Devlin
EBElisa Barbieri
Elisa Barbieri
DKDeborah A. Knight
Deborah A. Knight
RJRicky W. Johnstone
Ricky W. Johnstone

18 July 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
OKOtto Kauko
Otto Kauko
COCaitlin M. O’connor
Caitlin M. O’connor
EKEvgeny Kulesskiy
Evgeny Kulesskiy
JSJaya Sangodkar
Jaya Sangodkar
AAAnna Aakula
Anna Aakula
Jukka WestermarckJukka Westermarck
Jukka Westermarck
Pharmacological PP2A activation is a druggable approach to overcome MEK inhibitor resistance.

1 March 2018 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
OKOtto Kauko
Otto Kauko
Jukka WestermarckJukka Westermarck
Jukka Westermarck

28 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
KPKarolina Pavic
Karolina Pavic
NGNikhil Gupta
Nikhil Gupta
JOJudit Domènech Omella
Judit Domènech Omella
RDRita Derua
Rita Derua
AAAnna Aakula
Anna Aakula
Jukka WestermarckJukka Westermarck
Jukka Westermarck
The protein phosphatase 2A (PP2A) heterotrimer PP2A-B56α is a human tumour suppressor. However, the molecular mechanisms inhibiting PP2A-B56α in cancer are poorly understood. Here, we report molecular level details and structural mechanisms of PP2A-B56α inhibition by an oncoprotein CIP2A. Upon direct binding to PP2A-B56α trimer, CIP2A displaces the PP2A-A subunit and thereby hijacks both the B56α, and the catalytic PP2Ac subunit to form a CIP2A-B56α-PP2Ac pseudotrimer. Further, CIP2A competes with B56α substrate binding by blocking the LxxIxE-motif substrate binding pocket on B56α. Relevant to oncogenic activity of CIP2A across human cancers, the N-terminal head domain-mediated interaction with B56α stabilizes CIP2A protein. Functionally, CRISPR/Cas9-mediated single amino acid mutagenesis of the head domain blunted MYC expression and MEK phosphorylation, and abrogated triple-negative breast cancer in vivo tumour growth. Collectively, we discover a unique multi-step hijack and mute protein complex regulation mechanism resulting in tumour suppressor PP2A-B56α inhibition. Further, the results unfold a structural determinant for the oncogenic activity of CIP2A, potentially facilitating therapeutic modulation of CIP2A in cancer and other diseases.

26 February 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
OKOtto Kauko
Otto Kauko
SISusumu Imanishi
Susumu Imanishi
EKEvgeny Kulesskiy
Evgeny Kulesskiy
TLTeemu Daniel Laajala
Teemu Daniel Laajala
LYLaxman Yetukuri
Laxman Yetukuri
Jukka WestermarckJukka Westermarck
Jukka Westermarck
Systemic understanding of protein phosphatase 2A (PP2A)-regulated cellular processes is still at infancy. Here, we present mass-spectrometry analysis of phospho-targets (dephosphorylome) regulated by PP2A modulation. In addition to PP2A-regulated processes and targets, the data reveal important general concepts and rules related to PP2A-mediated phosphoregulation. These include the unidirectionality paradigm of regulation of phosphorylation, and differential spatial distribution of kinase-and phosphatase-dominated phosphotargets. Data also present first systemic analysis of targets of PP2A-modulating oncoproteins, CIP2A, PME-1, and SET; including targets via which PP2A may coordinately regulate activities of cancer drivers and tumor suppressors such as MYC or TP53. To validate functional utility of this dataset, PP2A dephosphorylome activity was correlated with cancer cell responses to over 300 drugs. Notably, we find that cancer therapy responses can be broadly classified based on PP2A dephosphorylome activity, both in quantitative and qualitative manner. In summary, our data characterize rules by which PP2A coordinate cancer cell phosphosignaling and drug responses. The results also may also direct the use of emerging pharmacological approaches for PP2A activity modulation in human diseases.

18 March 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
AAAnna Aakula
Anna Aakula
AIAleksi Isomursu
Aleksi Isomursu
CRChristian Rupp
Christian Rupp
AEAndrew Erickson
Andrew Erickson
OKOtto Kauko
Otto Kauko
Jukka WestermarckJukka Westermarck
Jukka Westermarck
While organ-confined PCa is mostly therapeutically manageable, metastatic progression of PCa remains an unmet clinical challenge. Resistance to anoikis, a form of cell death initiated by cell detachment from the surrounding extracellular matrix, is one of the cellular processes critical for PCa progression towards aggressive disease. Therefore, further understanding of anoikis regulation in PCa might provide therapeutic opportunities. Here, we discover that PCa tumors with concomitantly compromised function of two tumor suppressor phosphatases, PP2A and PTEN, are particularly aggressive, having less than 50% 5-year secondary-therapy free patient survival. Functionally, overexpression of PME-1, a PP2A inhibitor protein, inhibits anoikis in PTEN-deficient PCa cells. In vivo, PME-1 inhibition increased apoptosis in in ovo PCa tumor xenografts, and attenuated PCa cell survival in zebrafish circulation. Molecularly, PME-1 deficient PCa cells display increased trimethylation at lysines 9 and 27 of histone H3 (H3K9me3 and H3K27me3), a phenotype corresponding to increased apoptosis sensitivity. In summary, we discover that PME-1 overexpression supports anoikis resistance in PTEN-deficient PCa cells. Clinically, the results identify PME-1 as a candidate biomarker for a subset of particularly aggressive PTEN-deficient PCa.